Chromosomal translocation t(18;21)(q23;q22.1) indicates novel susceptibility loci for frontotemporal dementia with ALSкод для вставкиСкачать
Chromosomal Translocation t(18;21)(q23;q22.1) Indicates Novel Susceptibility Loci for Frontotemporal Dementia with ALS Johannes Prudlo, MD,1 Burkhard Alber, MD,2 Vera M. Kalscheuer, PhD,3 Klaus Roemer, PhD,4 Thomas Martin, MD,5 Joern Dullinger, MD,6 Helmut Sittinger, MD,7 Stephan Niemann, MD,8 Peter Heutink, PhD,9 Albert C. Ludolph, MD,2 Hilger H. Ropers, MD,3 Klaus Zang, MD,5 and Thomas Meyer, MD6 A chromosomal translocation t(18;21)(q23;q22) is reported in a patient with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We exclude the physical involvement and silencing of the ALS-linked gene for copper/zinc superoxide dismutase (SOD1) on chromosome 21q22.1. The breakpoints are assigned to sequences flanked by the markers ATA1H06, D18S462, D21S1915, and D21S1898. These critical regions may contain susceptibility loci for FTD associated with ALS. Ann Neurol 2004;55:134 –138 Two to 5% of amyotrophic lateral sclerosis (ALS) cases concurrently occur with frontotemporal dementia (FTD), a neurodegenerative disorder with personality changes and language dysfunction related to a primary progressive frontotemporal lobar atrophy.1– 4 For the familial form of FTD/ALS, a first genetic locus has been identified on chromosome 9q21-q22.5 Approximately 10% of ALS patients have inherited the disease. Ten to 20% of these patients have been linked to a locus on chromosome 21q22 and are caused by muta- From the 1Department of Neurology, University Hospital, Homburg/Saar; 2Department of Neurology, University of Ulm, Ulm; 3 Max Planck Institute for Molecular Genetics, Berlin; 4Department of Virology, University Hospital; 5Department of Human Genetics, University Hospital, Homburg/Saar; 6Department of Neurology, Charité University Hospital, Humboldt University, Berlin; 7Department of Psychiatry, University Hospital, Homburg/Saar; 8Department of Human Genetics, Justus-Liebig-University, Giessen, Germany; and 9Department of Clinical Genetics, Erasmus University, Rotterdam, The Netherlands. Received Mar 24, 2003, and in revised form Jun 23 and Sep 25. Accepted for publication Sep 25, 2003. Address correspondence to Dr. Johannes Prudlo, University Hospital, Department of Neurology, Kirrberger Strasse, 66421 Homburg/ Saar, Germany. E-mail: email@example.com 134 tions in the gene encoding copper/zinc superoxide dismutase (SOD1).6 Recently, we found constitutional chromosomal abnormalities in several apparently sporadic ALS patients, all affecting distinct chromosomal loci.7 We proposed that the chromosome rearrangements may represent a genomic risk factor for apparently sporadic ALS. Among these patients we identified a man aged 64 years with FTD and ALS carrying a balanced chromosomal translocation t(18;21)(q23; q22). The cytogenetic breakpoint on chromosome 21 localized to the region 21q22 which harbors the ALSassociated SOD1 gene. Here, the physical involvement and the silencing of the SOD1 gene by the chromosomal rearrangement was excluded. This suggests the presence of genetic susceptibility loci for FTD and ALS in previously undescribed genomic regions, one of them in the proximity of the SOD1 locus. Case Report The patient presented with a slowly progressive behavioral and affective disorder. Furthermore, there was a prominent cognitive dysfunction such as impairment of comprehension, perseveration, and bradyphrenia indicating prominent frontal executive deficits. Immediate free recall, attention, and calculation also were disturbed as shown by digit span subtest of the Wechsler Memory Scale (WMS) and logical memory subtest of the WMS. More complex tests (eg, verbal fluency, Trail Making Test) were not applicable. The diagnosis of FTD was established according to the Lund and Manchester criteria.8 Motor symptoms became evident within several months after the onset of dementia, consisting of gradually progressive bulbar palsy, weakness, wasting, and fasciculations. On examination, he showed a severe lower and upper motor syndrome that fulfilled the clinical criteria for the diagnosis of definite ALS.9 Furthermore, we observed a selective loss of upward vertical saccades, which is found in some ALS patients.10 Magnetic resonance imaging showed moderate midbrain atrophy as indicated by a decreased midsagittal anterioposterior diameter of the midbrain (Fig 1A).11 Upon further inspection with 18F-fluorodeoxyglucose positron emission tomography (PET), we found a significant decrease in glucose metabolism within the frontal and temporal lobes (see Fig 1B–D). Finally, examination by 123I-IBZM-SPECT showed an asymmetric and reduced striatal postsynaptic D2-receptor density, reflecting an extrapyramidal involvement, which has been described in ALS previously (see Fig 1E).3 After a total clinical course of 2.5 years, death resulted from recurrent aspiration pneumonia and respiratory insufficiency. Consent for an autopsy was not given. © 2003 American Neurological Association Published by Wiley-Liss, Inc., through Wiley Subscription Services Fig 1. Brain imaging. (A) Moderate midbrain atrophy indicated by a decreased midsagittal anterioposterior diameter (normal ⬎17mm) on axial T2-weighted MRI as depicted in the scheme. (B–D) PET images of 18F-fluorodeoxyglucose metabolism. Markedly reduced tracer uptake in both frontal and temporal lobes, axial (B) and midline sagittal plane (C), paramedian right temporal lobe (D). (E) 123I-IBZM-SPECT: reduced and asymmetric striatal postsynaptic D2-receptor density. Cytogenetic Analysis Cytogenetic analysis was conducted on G-banded chromosomes of cultured peripheral blood lymphocytes. Fluorescence in situ hybridization (FISH) analysis of mega-yeast artificial chromosome (YAC) clones from a genomewide YAC panel (YAC/BAC FISH mapping resource at the Max Planck Institute for Molecular Genetics, Berlin) were used to narrow the breakpoint on the chromosomes 21 and 18. The YACs are derived from the Centre d’Etude du Polymorphisme Humain YAC library and YAC descriptions refer to this library. SOD1 Gene Analysis To investigate whether the translocation breakpoint occurred within the SOD1 gene, we performed a Southern blot analysis (Fig 2A). Standard methods were used for probe labeling, hybridization, washing, and autoradiography. SOD1 exons 1 to 5 (complete cDNA sequence) in- cluding flanking intronic sequences were amplified by polymerase chain reaction (PCR). This was followed by direct sequencing of both strands of PCR products on an ABI-Prism 3100 DNA sequencer. Reverse Transcription Polymerase Chain Reaction Analysis For semiquantitative PCR of the SOD1 transcript, we conducted a reverse transcription (RT) and subsequent PCR amplification of two overlapping fragments of the SOD1 cDNA. The primer design and sequences are given in Figure 2C. RT-PCR was performed on equal amounts of lymphocyte total RNA (500ng) of three controls, the patient and the son of the index patient, who carried the same chromosomal abnormality. The semiquantitative RT-PCR was repeated thrice. Contamination was excluded with a blank PCR probe. Five microliters of PCR products was removed after 28, 30, 32, 34, 36, 38, and 40 cycles, respectively. Images were Prudlo et al: Susceptibility Loci for FTD/ALS 135 Fig 2. Analysis of the SOD1 gene locus. (A) Restriction sites of four DNA endonucleases ( BamHI, SacI, EcoRI, XbaI) in relation to the SOD1 gene used for the digestion of the genomic DNA. (B) Southern blot of genomic DNA of the patient (P) and three controls (C1, C2, C3) restricted with the endonucleases BamHI, SacI, EcoRI, XbaI (lanes 1– 4) hybridized with a radioactive probe of a 610bp fragment of the SOD1 complementary DNA (GenBank Accession number E00882). (C) Schematic presentation of a multiplex polymerase chain reaction (PCR) of the complete complementary DNA (primers F1-R1) and two overlapping fragments of the SOD1 transcript (5⬘-fragment: primers F1-R2; 3⬘-fragment: primers F2-R1). Primers used: SOD1-F1 (5⬘-CTGCAGCGTCTGGGGTTT-3⬘), SOD1-R1 (5⬘-CAGTGTTTAATGTTTATCAGGAT-3⬘), SOD1-F2 (5⬘-CAGTGAAGGTGTGGGGAA-3⬘), SOD1-R2 (5⬘-GTCCATTACTTTCCTTCTGC-3⬘). (D) Competitive PCR amplification of SOD1 mRNA in the patient (P) and a normal control. The SOD1 gene dosage effect is defined by the expression of a distinct PCR product (eg, product 1) in relation to the other PCR products (eg, products 2 and 3) of the same patient. M ⫽ marker (100bp). captured by ultraviolet translumination (GelDoc1000; Bio-Rad, Richmond, CA). Quantitative expression of SOD1 transcript was determined at cycle 38 during linear regression of amplification. Results Karyotype Analysis The karyotype analysis of the index patient has been reported showing an apparently balanced translocation t(18;21)(q23;q22) (Fig 3).7 In addition, the index patient’s 37-year-old son who was clinically unaffected was found to carry the same constitutional chromosomal rearrangement. The mother and two sisters of the patient were karyotypically normal. 136 Annals of Neurology Vol 55 No 1 January 2004 Mapping of Chromosomal Breakpoints Using Fluorescence In Situ Hybridization FISH analysis on chromosome 18 with YAC 932B10 (118cM) identified signals on 18q23, der(18), and der(21). Thus, the breakpoint is localized between YAC STS markers ATA1H06 and D18S462 spanning a 1Mb region. The breakpoint on chromosome 18 mapped at least 17Mb distal from a recently reported gene locus of familial ALS.12 The breakpoint region on 21q22 is flanked by the proximal YAC 752D12 with STS D21S1915 (29cM) and the distal YAC 901E1 with STS D21S1898 (35cM). YAC 752D12 maps to chromosome 21 and to der(21), whereas the YAC 901E1 maps to chromosome 21 and der(18) localizing the breakpoint in a 6Mb region including the SOD1 gene. Fig 3. Representative G-banded karyotype of the index patient. The cytogenetic analysis is showing an apparently balanced translocation in the 46,XY,t(18;21)(q23;q22.1) karyotype. The arrowheads indicate the breakpoint positions. The SOD1 Gene Locus The SOD1 probe detected the expected restriction pattern of one (BamHI, SacI, EcoRI) and two (XbaI) bands, respectively (see Fig 2B, lanes 1– 4). Several bands of other molecular weights were detected and likely represent restriction products of known SOD1 pseudogenes. One of them is visible in the Figure 2B, EcoRI. Importantly, no alteration of the DNA restriction pattern was observed in our patient, as compared with three controls. Southern analysis did not indicate a disruption of SOD1 locus. Furthermore, no mutation was identified by sequence analysis of SOD1 exons 1 to 5 (complete cDNA sequence) including flanking intronic sequences in genomic DNA (data not shown). Expression of SOD1 RNA Amplification of the SOD1 cDNA and two overlapping fragments yielded PCR signals of 617, 468, and 149bp, respectively. However, no differences in signal intensity were observed in our patient when compared with the PCR signals of a nonneurological control (see Fig 2D), and in the patient’s son (data not shown). This result indicates that the SOD1 expression is not silenced by the translocation. Moderately altered expression of the SOD1 transcript, however, could not be excluded by the semiquantitative PCR method. The Tau Gene Mutation analysis of the complete coding region of the tau gene including the exon/intron boundaries, performed on the patient’s genomic DNA by direct sequencing, failed to show any sequence alterations. Discussion Karyotype analysis of our index patient demonstrated a chromosomal breakpoint on chromosome 21q22, the cytogenetic region of the ALS-linked SOD1 gene.7 This observation raised the question whether the genomic rearrangement has disrupted the SOD1 locus.6 We excluded a physical involvement of the SOD1 gene. Also, there was no evidence for a position effect and silencing of the SOD1 gene. Furthermore, the translocation breakpoint was narrowed to a 6Mb genomic region on chromosome 21q22.1, flanked by the markers D21S1915 and D21S1898. Given this physical proximity to the SOD1 gene, it is conceivable that the genomic rearrangement interacts in some way with the SOD1 locus. This possibility is supported by the report of a disease-modifying factor in close proximity but outside the SOD1 gene, which is shared by recessive kindreds of the unique SOD1-D90A mutation.13 In a series of apparently sporadic ALS patients, we previously identified a high rate of constitutional chromosomal abnormalities (⬎5 %).7 This frequency is significantly higher than the frequencies in the general population, as reported in three different studies.14 –16 However, these historical controls are not optimal, and a better control population would have been asymptomatic subjects studied in a blinded fashion during the actual karyotyping of the patients. Frequencies of chromosome abnormalities are mostly derived from large-scale incidence studies in newborns or amniocen- Prudlo et al: Susceptibility Loci for FTD/ALS 137 tesis, which show a prevalence of balanced rearrangements in 0.1 to 0.28%.14 –16 Family studies of ALS patients identified several asymptomatic carriers of constitutional rearrangements, including some of advanced age.7 These findings suggest that in conjunction with the chromosomal abnormalities, other genetic or external factors may be required to produce the clinical phenotype.16 This observation contributes to the current concept that apparently sporadic FTD and ALS represent complex disorders in which modifying genes and environmental agents can contribute to the risk of disease. We examined genome databases for possible candidate genes in the cytogenetic regions of rearrangements on both involved chromosomes. Several genes map near the breakpoint regions on chromosome 21 (encoding ubiquitin specific protease, the glutamate receptor of the kainate subtype, claudin, synaptojanin, and interferon receptor 2) and the candidate region on chromosome 18 (encoding galanin receptor 1, zinc finger protein 236, myelin basic protein). The characterization of the breakpoint regions on chromosomes 21 and 18 using positional cloning will help to define critical sequences in the human genome which predispose to FTD and ALS. It remains to be determined whether the chromosomal rearrangements define sets of functionally significant genes. If this is the case, an understanding of the associated proteins and pathways may provide further insight into the genetic risk of FTD and ALS. This work was supported by the VERUM Foundation, Munich (T. M.) and the German Genome Programme (01KW99087, T. M.). We thank H. Madle, C. Menzel, and U. Reuter for technical assistance. We are especially grateful to Drs Kirsch and Moellers for providing the SPECT and PET images. References 1. Snowden JS, Neary D, Mann D. Frontotemporal dementia. Br J Psychiatry 2002;180:140 –143. 2. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59:1077–1079. 3. Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981;104:217–247. 4. Morris HR, Khan MN, Janssen JC, et al. The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol 2001;58:1813–1816. 5. Hosler BA, Siddique T, Sapp PC, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21–q22. JAMA 2000;284:1664 –1669. 6. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59 – 62. 7. Meyer T, Alber B, Roemer K, et al. High rate of constitutional chromosomal rearrangements in apparently sporadic ALS. Neurology 2003;60:1348 –1350 138 Annals of Neurology Vol 55 No 1 January 2004 8. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998;51:1546 –1554. 9. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:96 –107. 10. Averbuch-Heller L, Helmchen C, Horn AKE, et al. Slow vertical saccades in motor neuron disease: correlation of structure and function. Ann Neurol 1998;44:641– 648. 11. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697–702. 12. Hand CK, Khoris J, Salachas FA, et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2002;70:251–256. 13. Parton MJ, Broom W, Andersen PM, et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype. Hum Mutat 2002;20:473– 480. 14. Nielsen J, Wohlert M. Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in Århus, Denmark. Hum Genet 1991;87:81– 83. 15. Jacobs PA, Browne C, Gregson N, et al. Estimates of the frequency of chromosome abnormalities detectable in unselected newborns using moderate levels of banding. J Med Genet 1992; 29:103–108. 16. Bugge M, Bruun-Petersen G, Brondum-Nielsen K, et al. Disease associated balanced chromosome rearrangements: a resource for large scale genotype-phenotype delineation in man. J Med Genet 2000;37:858 – 865. 17. Burghes AH, Vaessin HE, de la Chapelle A. Genetics. The land between Mendelian and multifactorial inheritance. Science 2001;293:2213–2214.